Biogen | BIIB - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Acadia Pharmaceuticals USD 272.68M 6.08M 2026-03
ALKERMES USD 1.75B 1.43B 2026-03
Amgen USD 4.78B 1.12B 2026-03
Bayer EUR 9.88B 452M 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Eli Lilly USD 10.02B 285M 2026-03
Esperion Therapeutics USD 83.21M 14.06M 2025-12
Gilead Sciences USD 23.52B 18.55B 2026-03
Incyte USD 5.62B 4.5B 2026-03
Merck USD 18.17B 8.01B 2026-03
Moderna USD 1.78B 242M 2026-03
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Novartis USD 9.29B 507M 2026-03
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Sanofi EUR 10.71B 1.32B 2025-12
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Teva Pharmaceutical Industries USD 3.22B 1000M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
United Therapeutics USD 5.9B 5.1B 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03